entertainment -WSS

entertainment

author：explore 2025-09-30 00:36:39 - browse：23

A judge ruled that Welsh Carson won't have to face antitrust allegations about its anesthesiology practice. Adobe

Welsh, Carson, Anderson & Stowe has wiggled out of the grasp of the Federal Trade Commission, but the private equity firm’s anesthesia company, U.S. Anesthesia Partners, still must face the agency’s antitrust case, a judge ruled last week.

The FTC alleged last year that the anesthesiology network monopolized markets in Texas to drive up prices, but took the unusual step of attaching Welsh Carson as a defendant with USAP. Dismissing Welsh Carson from the case was a victory for the private equity firm and, more broadly, other firms worried that the Biden administration would try to hold them responsible for anything their portfolio companies do.

But the allegations against USAP didn’t disappear, which will keep up scrutiny on companies that have made a push to acquire numerous physician groups.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： How neuroscience research could help beat back brain cancer

focus

WSS

Biden announces an advanced cancer research initiative

Bill would allow buprenorphine prescription for addiction via telehealth

Inari Medical to buy amputation prevention company LimFlow

Trader Joe's recalls 10K cases of broccoli cheddar soup over potential foreign material

How neuroscience research could help beat back brain cancer

Coloradans with cystic fibrosis could lose access to Trikafta

knowledge

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

hotspot

Drug repurposing or repositioning? The language matters

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Guidelines to prevent youth baseball injuries need more muscle

Gene therapy’s promise and the high cost of hope

ChatGPT in medicine: STAT answers readers' burning questions

The mammogram wars are not over

Tori Bowie and the unacceptable rates of Black maternal death

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

At least 13 dead in Texas as scorching temps continue

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

hotspot

Stoke drug shows lower activity against childhood epilepsy

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Life sciences investors close nearly $6 billion in new funds

Ending health disparities requires full federal government, panel says

Timeline: Special counsel's probe into Trump's handling of classified documents

The health care issue Democrats can’t solve: hospital reform

knowledge

knowledge

focus

leisure time